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The association of breast cancer with passive and active smoking was investigated in slow and fast
acetylators of aromatic amines in a Geneva, Switzerland, study in 1996–1997. A slow acetylator was
homozygous for one, or heterozygous for two, of three N-acetyltransferase 2 (NAT2) polymorphisms determined
on buccal cell DNA from 177 breast cancer cases and 170 age-matched, population controls. The reference
group consisted of women never regularly exposed to active or passive smoke. Among premenopausal women,
the odds ratios were homogeneous in slow and fast acetylators: 3.2 (95% confidence interval (CI): 1.2, 8.7) for
passive smoking and 2.9 (95% CI: 1.1, 7.5) for active smoking. Among postmenopausal women, the odds ratios
for fast acetylators were 11.6 (95% CI: 2.2, 62.2) for passive and 8.2 (95% CI: 1.4, 46.0) for active smoking; the
corresponding effects were also apparent but less strong in slow acetylators. After the nonexposed and the
passive smokers were grouped in a single reference category, active smoking was associated with
postmenopausal breast cancer in slow acetylators (odds ratio (OR) = 2.5, 95% CI: 1.0, 6.2) but not in fast
acetylators (OR = 1.3, 95% CI: 0.5, 3.3). Thus, the associations of both passive and active smoking with breast
cancer appear stronger in fast than in slow NAT2 genotypes. Separating passive smokers from the nonexposed
impacts on the inference about a possible NAT2-smoking interaction. Am J Epidemiol 2000;152:226–32.
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Suspicions that breast cancer may be linked to passive
smoking go back to 1985, when Sandler et al. (1) observed
a twofold increased risk of breast cancer associated with
smoking by spouse. They postulated that in previous stud-
ies, “… nonsmokers may have included women who were
passively exposed, limiting the possibility of observing any
effect that might result from exposure to sidestream smoke”
(2, p. 371). They therefore suggested, “Future studies of this
question should collect data that will allow for stratification
into at least three smoking categories: true nonexposed,
those with passive exposure only, and active smokers” (2, p.
371).
Indeed, six studies (3–8), recently reviewed by Wells (9),
have been conducted or reanalyzed according to this
methodological recommendation. Five of them (3–7) were
based on incident cases and consistently show that women
exposed to passive smoking are at increased risk of breast
cancer relative to women never exposed to either active or
passive smoke (10). The association of breast cancer was of
similar magnitude with passive smoking (odds ratio (OR) 
2.0, 95 percent confidence interval (CI): 1.5, 2.6) and with
active smoking (OR  2.2, 95 percent CI: 1.6, 2.9).
It has also been found that women who are active smok-
ers and slow acetylators due to their N-acetyltransferase 2
(NAT2) genotype were at increased risk of breast cancer
(11), suggesting that slow acetylation of aromatic amines
may lead to a longer or greater exposure to some of the
potentially carcinogenic compounds than fast acetylation.
However, of the three studies (12–14) that tried to reproduce
the findings of Ambrosone et al. (11), none showed higher
relative risks among slow acetylators as clearly.
We had postulated that the NAT2-smoking interaction
could explain the similar magnitude of effect of passive and
active smoking on breast cancer risk; that is, women who
develop breast cancer as a consequence of passive smoking
would be more likely to be slow acetylators (15). We tested
this hypothesis by obtaining buccal scrapes and isolating the
desoxyribonucleic acid (DNA) from all surviving cases and
from a random sample of age-matched controls drawn from
the case-control study conducted in 1992–1993.
MATERIALS AND METHODS
A population-based case-control study was performed
during 1992–1993 in Geneva, Switzerland (3). Eligible
cases were all women resident in Geneva aged less than 75
years diagnosed with incident breast cancer. We interviewed
71 percent (n  244) of 344 eligible cases and 70 percent of
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1,032 eligible controls, who were a random sample of
women aged 30–74 years residing in Geneva during the
same time period. Cases and controls were invited to come
to a mobile clinic and participate in an ongoing survey on
women’s health. The aim of the study was not specified, and
trained interviewers were blind to the case-control status.
The smoking history section of the questionnaire was struc-
tured as four calendars, with one dedicated to active smok-
ing and three separate calendars dedicated to passive expo-
sures at home, at work, and during leisure time. Smoking
exposures were recorded year by year, between age 10 and
the date of interview. An episode of exposure consisted of a
time period of at least 6 months during which the woman
had passively or actively smoked. For each episode of active
smoking, the number of cigarettes per day, filter, and ciga-
rette brand were recorded. The number of hours per week of
each passive smoking episode was recorded.
The present gene-smoking interaction study was con-
ducted in 1996–1997. As no biologic material was collected
in the original study (1992–1993) in view of a genetic study,
we first identified the surviving cases from a computerized
database indicating whether a person had remained a resi-
dent of Canton Geneva and, if applicable, whether the per-
son was still living. We could identify 205 cases (84 percent)
still alive and residing in Geneva. A group of frequency-
matched controls were randomly selected so that the pro-
portion of controls within each 10-year age group was sim-
ilar to that of the cases. Of the 349 women selected, 287
(82.2 percent) were still residing in Geneva and eligible. A
letter describing the aim of the study was sent to all eligible
subjects. In case of nonresponse, we tried to contact every
eligible person by telephone.
Participants were asked to come to the Division of
Clinical Epidemiology of the Geneva University Hospital.
All women signed an informed consent for DNA analysis.
Cells were collected from the cheek mucosa using a cyto-
logic brush. This approach minimized nonparticipation by
eligible subjects.
Procedures at the laboratory
Buccal cells were sampled with two cytologic brushes per
patient. After sample collection, the brushes were put imme-
diately into 400 µl of 6 M sodium iodide. Samples were
stored at 4˚C before extraction. Total DNA was extracted by
binding to a silica matrix (Prepagene; Bio-Rad, Hercules,
California) in groups of 96 samples to allow manipulation in
a microtiter plate format (QIAamp 96 DNA blood kit;
Qiagen AG, Basel, Switzerland). DNA was extracted up to
6 months after sampling, with no apparent effect on effi-
ciency. Two separate extractions were performed for each
person. DNAs were stored in 10 mM Tris/0.1 mM ethylene
diamine tetraacetic acid, at 4˚C and at –80˚C (duplicates).
Three polymorphisms of the arylamine-N-acetyltransferase
2 gene (NAT2) were analyzed by nested polymerase chain
reaction and restriction digestion. A 900-base pair fragment
containing the entire coding region of NAT2 was amplified
(30 cycles, standard conditions); then 1 µl of this product was
subjected to nested polymerase chain reaction to amplify a
740-base pair fragment containing the sites of the three func-
tionally important polymorphisms 481 (KpnI restriction frag-
ment length polymorphism (RFLP)), 590 (TaqI RFLP), and
857 (BamHI RFLP). The polymerase chain reaction primers
were the following: first polymerase chain reaction, NAT2CL
(GCC ATG GAG TTG GGC TTA GAG), NAT2R (GTG AGT
TGG GTG ATA CAT ACA CAA G); nested polymerase chain
reaction, NAT2DL (ATT TTT GAT CAC ATT GTA AGA
AGA), NAT2CR (CAT ACA CAA GGG TTT ATT TTG TTC
C). The polymorphic sites were analyzed by serial digestion
with the appropriate restriction enzymes followed by elec-
trophoresis on horizontal 12 percent polyacrylamide gels
(GenePhor; Amersham Pharmacia Biotech, Piscataway, New
Jersey). Samples were coded so that the laboratory was
unaware of the case-control status. They were analyzed twice,
and the gels were interpreted independently, with complete
concordance. A total of 347 samples were given to the labo-
ratory, of which 330 (95 percent) were successfully amplified.
The failure to amplify 5 percent of samples was a conse-
quence of using cheek scrapes as source material and was
deemed acceptable. The restriction digestion results of 94
samples could not be unequivocally interpreted, and these
samples were analyzed by direct sequencing of polymerase
chain reaction products using Thermosequenase and an ALF
Express DNA sequencer (Pharmacia). Unequivocal results
were thus obtained for 322 samples (93 percent).
Statistical methods
Information concerning exposure to tobacco smoke was
obtained from the original interview. Ever smokers had
smoked at least 100 cigarettes in their lifetime. Among ever
smokers, current smokers were women who reported having
smoked regularly within the 2 years preceding interview.
Passive smokers were defined as women who had been
exposed at least 1 hour per day during 1 year or more either
at home, at work, or during leisure time.
A woman was defined as a slow acetylator if she was
homozygous for one, or heterozygous for two, of the three
following NAT2 polymorphisms: 481C>T (KpnI RFLP),
590G>A (TaqI), and 857G>A (BamHI). This definition
assumed that there could be no single allele with two or
more of the tested mutations (11, 16).
The odds ratios for developing breast cancer can be inter-
preted as relative risks of breast cancer. They were estimated
using a logistic regression model that included as potential
confounders the three variables that appeared to be related to
breast cancer in the full sample, that is, age, education, and
positive family history of breast cancer. Analyses were also
stratified by menopause, defined as having had the last menses
at least 1 year before interview or a bilateral ovariectomy.
A possible interaction among NAT2, smoking, and breast
cancer was investigated using multiple logistic regression.
Multiplicative interaction was assessed by adding a product
term between NAT2 status and each smoking exposure. The
interaction coefficient can be interpreted as the log of the
ratio of the smoking by breast cancer odds ratios in fast rel-
ative to slow acetylators. Additive interaction was assessed
by the relative excess risk due to interaction that was esti-
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mated (with its 95 percent confidence limits) according to
the method of Hosmer and Lemeshow (17).
As DNA could not be analyzed for 25 women (10 cases and
15 controls), we performed a sensitivity analysis with four
hypothetic scenarios: 1) all 25 missing subjects were fast
acetylators; 2) all 25 missing subjects were slow acetylators;
3) missing cases were slow acetylators but controls were fast
acetylators; and 4) missing controls were slow acetylators but
cases were fast. Results of the four scenarios were highly con-
sistent with those obtained without the 25 women.
RESULTS
Of the 205 cases from the original study who could poten-
tially participate in this study, 170 agreed to participate (83
percent). Differences in breast cancer risk factors and in
smoking status between this subsample and the original case
series can be obtained by comparing tables in the present
paper with tables of the original publication (3). Deficits of
participation were found in the following categories: pri-
mary education, nulliparity, and never oral contraceptive
use. The proportion of ever passive smokers was 44 percent
in the present sample and 34 percent in nonparticipants.
Corresponding proportions of ever active smokers were 47
percent and 51 percent.
Of the randomly sampled subgroup of 287 control
women, 177 (62 percent) participated. DNA was success-
fully analyzed in 160 cases and 162 controls (93 percent).
Except for age matching and for a lower participation of
women with primary education, characteristics of the pres-
ent sample of controls were very similar to those of the non-
participants.
Table 1 shows that the compared groups had the same age
distribution. There were a reduction in risk of breast cancer
with older age at menarche and an increased risk in women
with age at first birth between 25 and 29 years and in women
with a family history of breast cancer.
The allele frequencies of the NAT2 genetic variants were
46.1 percent for 481T, 27.6 percent for 590A, and 4.7 per-
cent for 857A. These frequencies are in close agreement
with those published by Cascorbi et al. (16) for the German
population. The overall frequency of slow acetylation geno-
types was 56.5 percent. It was slightly higher among cases
(58.8 percent) and among passive (58.7 percent) or active
(57.6 percent) smokers, but these differences were not sta-
tistically significant.
When pooling premenopausal and postmenopausal
women, we found the adjusted odds ratio of breast cancer to
be 3.1 (95 percent CI: 1.5, 6.0) for passive smokers and 3.3
(95 percent CI: 1.7, 6.5) for active smokers (not shown in a
table). After stratification for NAT2 (table 2), both active and
passive smoking increased breast cancer risk, with higher
relative risks observed for the fast acetylation genotype. The
one apparent exception, the current smokers of less than 20
cigarettes per day, may be an effect of the small size of this
subgroup.
Among premenopausal women (89 cases and 93 con-
trols), odds ratios were homogeneous in slow and fast acety-
lators (figure 1): the NAT2-adjusted odds ratio was 3.2 (95
percent CI: 1.2, 8.7) for passive smoking and 2.9 (95 percent
CI: 1.1, 7.5) for active smoking (not shown in a table).
Among postmenopausal women (81 cases and 84 con-
trols), a strong and statistically significant association was
found in fast acetylators with both passive (OR  11.6, 95
percent CI: 2.2, 62.2) and active (OR  8.2, 95 percent CI:
1.4, 46.0) smoking (figure 1). In slow acetylators, a smaller
effect was also apparent for active smoking (OR  2.9, 95
percent CI: 0.8, 11.2) but not for passive smoking (OR  1.1,
95 percent CI: 0.3, 4.3). The number of unexposed cases was
small in both slow (n  5) and fast (n  2) acetylators. In the
analyses of interaction, the ratio of odds ratios for fast rela-
tive to slow acetylators was 11.6 (95 percent CI: 1.3, 111.1)
for passive smoking and 3.3 (95 percent CI: 0.4, 33.3) for
active smoking. The relative excess risk due to interaction
was 5.1 (95 percent CI: –4.1, 14.2) for passive smoking and
2.9 (95 percent CI: –6.2, 12.0) for active smoking.
We also categorized passive smokers according to the
number of hours-per-day-years (3) of exposure, but these
analyses did not lead to different interpretations (not shown).
The median age of first exposure was 20 years for passive
and 18 years for active smoking. We used these cutoffs to
determine whether the effect of age at first exposure differed
according to NAT2 status. Nonexposed women were not
included in these analyses. The odds ratios for first exposure
to passive smoking at age 20 or before (relative to after age
20) were 1.6 (95 percent CI: 0.7, 3.9) in slow acetylators and
0.6 (95 percent CI: 0.2, 1.7) in fast acetylators (p for interac-
tion  0.15). The corresponding odds ratios for first active
smoking at age 18 or before (relative to after age 18) were
1.2 (95 percent CI: 0.6, 2.7) in slow and 0.4 (95 percent CI:
0.2, 1.1) in fast acetylators (p for interaction  0.10).
In order to compare the present results with those of pre-
vious reports that lacked information on passive smoking
(11–14), we repeated the analyses after grouping the nonex-
posed and the passive smokers in a single category. Among
premenopausal women, there was no significant association
for active versus never-active smokers in either slow (OR 
1.3, 95 percent CI: 0.5, 3.0) or fast (OR  1.5, 95 percent
CI: 0.6, 4.3) acetylators. In contrast, among postmenopausal
women, active smoking was a risk factor for breast cancer in
slow acetylators (OR  2.5, 95 percent CI: 1.0, 6.2) but not
in fast acetylators (OR  1.3, 95 percent CI: 0.5, 3.3). The
test for multiplicative interaction had p  0.30.
DISCUSSION
The biologic rationale behind studying NAT2 was that
tobacco bicyclic aromatic amines, such as β-naphthylamine
and 4-aminobiphenyl, are environmental carcinogens for the
breast. These amines are proven animal bladder carcinogens.
Human subjects with the slow NAT2 genotype or phenotype
are at higher risk of bladder cancer than are fast acetylators
(18). Ambrosone et al. (11) reported an increased risk of
postmenopausal breast cancer with active smoking in slow
acetylators only, suggestive of a NAT2-smoking interaction
with respect to breast cancer risk.
We expected to find a stronger association of smoking
and breast cancer in slow acetylators (15), but we found
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instead more elevated relative risks for both passive and
active smoking in fast acetylators, especially among post-
menopausal women. If true, these results suggest that the
carcinogenic substrate is not aromatic amines (which are
found only as traces in tobacco smoke) but heterocyclic
amines that are more concentrated in cigarette smoke than
bicyclic aromatic amines and are at least 10 times more pres-
ent in the sidestream than in the mainstream smoke. The
ratio of sidestream to mainstream smoke is probably even
greater in cigarettes with a perforated filter tip that is usually
smoked by women. Heterocyclic amines, such as pyridine,
are N-hydroxylated by cytochrome P450 1A2 and subse-
quently activated by O-acetylation by NAT2 to form elec-
trophilic intermediates and DNA adducts that can initiate
cancer (19, 20). If heterocyclic amines were the culprit, then
fast acetylators would be most at risk. An analogy can be
made here with colon cancer, which seems to be caused by
dietary heterocyclic amines and for which a higher risk in
fast acetylators has been consistently reported (21). A rela-
tion of breast cancer to dietary heterocyclic amines is not
well established (22) but is strongly supported by the results
of the Iowa Women’s Health Study (23).
Independently of the environmental agent involved, the
equivalence of relative risk of breast cancer for passive or
TABLE 1. Risk factors for breast cancer in 170 cases and 177 controls, Geneva, Switzerland,
1992–1994
Age (years)
<40
40–44
45–49
50–54
55–59
60–64
65–69
70–74
Education
Elementary
Apprenticeship
≥High school
BMI* (kg/m2)
<21
21–22
23–25
≥26
Age at menarche (years)
<12
12
13
14
≥15
Age at first live birth (years)‡
<25
25–29
≥30
No birth
No conception
Oral contraception
Never
Ever
Breast cancer in mother or sister
No
Yes
8
12
38
33
28
23
14
14
21
97
52
40
48
39
43
24
33
52
38
23
44
47
33
15
31
73
97
153
17
8
13
37
44
29
20
13
13
15
88
74
52
43
45
37
21
42
39
36
39
54
37
36
19
30
72
105
166
11
1.0
0.8
0.8
0.5
0.7
0.9
0.8
0.9
1.0
0.7
0.4
1.0
1.3
1.0
1.2
1.0
0.6
1.0
0.8
0.4
1.0
1.8
1.1
1.0
1.3
1.0
1.0
1.0
2.0
0.2, 3.0
0.2, 2.4
0.2, 1.7
0.2, 2.3
0.3, 3.0
0.2, 3.1
0.2, 3.5
0.3, 1.6
0.2, 0.9
0.7, 2.4
0.5, 2.0
0.6, 2.3
0.3, 1.3
0.5, 2.2
0.4, 1.8
0.2, 1.0
1.0, 3.4
0.6, 2.1
0.5, 2.4
0.6, 2.8
0.6, 1.7
0.9, 4.7
Risk
factor
Cases
(no.)
Controls
(no.) OR*,† 95% CI*
* OR, odds ratio; CI, confidence interval; BMI, body mass index.
† The odds ratio for each variable was controlled for all of the other factors in the table.
‡ Age of the first live birth missing for one control.
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FIGURE 1. Odds ratio of breast cancer with ever passive or ever active smoking by N-acetyltransferase 2 (NAT2) genotype in pre- and post-
menopausal cases and controls, Geneva, Switzerland, 1992–1994. The reference group is women never regularly exposed to active or passive
smoking. Odds ratios are simultaneously adjusted for age, education, and family history of breast cancer. Numbers in parentheses, 95% confi-
dence interval.
active smoking consistently reported (3–8) remains counter-
intuitive. A priori, passive smokers are less exposed than
active smokers who inhale their own and other people’s cig-
arettes’ sidestream smoke in addition to drawing puffs of
concentrated smoke aerosols. Many compounds of interme-
diate tobacco combustion are more concentrated in the side-
stream than in the mainstream smoke (when titrated by
smoke collector devices), but the inhaled concentration is
much diluted in the ambient air. It is, however, also impor-
tant to stress that the magnitude of the exposure of the pas-
sive smoker is often underestimated. We have reported that
the average lifetime exposure to passive smoke of the pres-
ent study control population was equivalent to 30.8
hours/week during 10 years or 20.5 hours/week during 15
years (24).
Analogic thinking with the tobacco-lung cancer associa-
tion also leads to expecting a huge relative risk differential
between active and passive smokers. The lung cancer
TABLE 2. Odds ratio of breast cancer with passive and active smoking, by NAT2 acetylation genotype,
Geneva, Switzerland, 1992–1994
Slow‡
Fast‡
Never exposed
Ever passive smokers
Ever active smokers
Exsmokers
Current <20 cpd*
Current ≥20 cpd
Never exposed
Ever passive
Ever active
Exsmokers
Current <20 cpd
Current ≥20 cpd
10
38
46
25
12
9
6
30
30
14
6
10
18
36
34
18
7
9
23
22
29
11
10
8
0.7, 4.6
1.1, 6.6
1.05, 7.8
1.05, 12.9
0.7, 6.9
2.0, 17.4
1.5, 12.0
1.5, 18.0
0.7, 12.7
1.4, 20.5
Acetylation
genotype
Smoking
status
Breast cancer
cases (no.) OR*,† 95% CI*
* OR, odds ratio; CI, confidence interval; cpd, cigarettes per day.
† Test of interaction among acetylation genotype, ever smoking status, and breast cancer, p = 0.54.
‡ Simultaneously adjusted for age, education, and family history of breast cancer.
1.0
1.9
2.7
2.8
3.7
1.6
1.0
5.9
4.2
5.2
3.1
5.3
Controls
(no.)
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model may, however, not be relevant for the mammary
gland that is not directly exposed to tobacco smoke.
Carcinogens need to circulate in the blood before reaching
the gland and seem to be able to remain for a very long time
in the mammary epithelial cells (25, 26). Environmental
tobacco smoke particles are small and therefore poorly fil-
trated by the lung. The risk differential between passive and
active smokers may therefore be smaller for breast than for
lung cancer.
In addition, the relative risk observed for passive smokers
may also be magnified by the low dose effect hypothesis
formulated by Vineis and McMichael (21) for colon cancer:
the modifying effect of a genotype or phenotype can be
more evident at low dose. In the present study, it is reason-
able to conceive that high levels of exposure to tobacco
smoke saturate the NAT2 enzyme activity, resulting in for-
mation of abundant DNA adducts from O-acetylation of
hydroxylated human carbonic anhydrase in both slow and
fast acetylators. In contrast, at low doses of exposure to
tobacco, DNA adducts may accumulate only among fast
acetylators, because, among slow acetylators, the N-acetoxy
derivatives are either produced in too small a quantity or
detoxified at the same rate they are produced.
Whether the first exposure to tobacco as a teenager deter-
mines the risk of breast cancer remains elusive (27–30). The
present study shows a reduced risk of young age at first
exposure to active and passive smoking among fast acetyla-
tors. Larger studies of gene-smoking interactions are needed
in populations where it is not uncommon that women start
to smoke before age 16.
An important observation from the present study for
future research on the relation of smoking to breast cancer is
that taking passive smoking into account had dramatic con-
sequences on inference. It was intriguing to observe that,
when active smokers were compared with never-active
smokers, a reference category that includes both unexposed
women and passive smokers, results suggested that post-
menopausal slow acetylators were at higher risk of breast
cancer if they smoked. This conclusion is consistent with the
study of Ambrosone et al. (11). On the other hand, when
nonactive, nonpassive smokers were used as the reference
category, analyses led to the opposite conclusion; that is,
postmenopausal fast acetylators were at higher risk of breast
cancer if they smoked. We consider the latter results as
being more valid, because it is logical to use the lowest level
of exposure to tobacco as the reference category, especially
in view of the epidemiologic evidence of a specific effect of
passive smoking (3–8).
Given the small number of cases, confidence intervals
were wide, and only very large effects could be detected
with sufficient statistical power. This limitation was particu-
larly problematic for the analyses of interaction. Even in the
multiplicative model for passive smoking, the low statistical
power did not allow us to establish whether the interaction
was quantitative (that is, association present in both fast and
slow acetylators but with a difference of magnitude) or qual-
itative (that is, association only among fast acetylators).
Thus, larger studies are needed to elucidate gene-smoking
interactions with statistical confidence.
Other limitations include the unexpected reduction in risk
of breast cancer observed in the more educated women 
(OR  0.4, 95 percent CI: 0.2, 0.9) that is inconsistent with
what is usually known about the etiology of this disease (31)
and that can be attributed to the differential participation of
educated women between cases and controls. This imbal-
ance was taken into consideration in the analysis by adjust-
ing the odds ratio for education and does not seem to have
generated substantial bias, since the observed effects for
smoking or other risk factors of breast cancer were consis-
tent with our previous findings (3) and with what is usually
found by others (31).
There could have been concerns about survival bias, since
biologic material was collected among survivors of the orig-
inal study. However, given the high survival rate (84 per-
cent), it is unlikely that results would have been markedly
different had the DNA specimens been collected at the time
of the original study.
It has been reported that smoking may reduce the risk of
breast cancer in women with mutant BRCA1 or BRCA2 (32).
This finding is only marginally relevant for epidemiologic
investigations in the general population because less than
one in every 500 women in the general population carries
these mutant genes (33).
In conclusion, the risk of breast cancer related to smoking
appears to be stronger in fast acetylators of aromatic amines.
Separating passive smokers from the nonexposed has major
implications on the inference about a possible NAT2-smok-
ing interaction.
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